PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes

Informacje na temat projektu

PanINSULA

Identyfikator umowy o grant: 828384

DOI

10.3030/828384

Projekt został zamknięty

Data podpisania przez KE 19 Lipca 2018

Data rozpoczęcia 1 Sierpnia 2018

Data zakończenia 30 Listopada 2018

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

PANCRYOS APS
Denmark

Periodic Reporting for period 1 - PanINSULA (PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes)

Okres sprawozdawczy: 2018-08-01 do 2018-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Type 1 Diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stop producing insulin - the hormone that controls blood-sugar levels. Insulin therapy, CGMs and insulin pumps try to mimic the function of the beta cell and require the patient or a computer to perform many of the steps such as testing blood, evaluating the results and administering insulin. PanCryos is developing a next generation stem cell derived therapy, PanINSULA, to treat T1D naturally without the need for outside intervention. The overall objectives of the project are implementing a GMP-compliant production protocol and clinically validating PanINSULA.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

During Phase 1 PanCryos assessed both the technical and business feasibility of PanINSULA. A product development plan addressing production setup and clinical validation requirements to ensure PanINSULA market readiness was drafted. Third parties to participate in the product development were contacted. A market assessment (including assessment of market size, customers and competitors) was carried out, the business model was refined and financial projections were prepared.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Pancryos patented technology, in contrast to other available competing technologies, enables both purification and automation ensuring unparalleled safety and cost-efficient scalability and manufacturability of the final cell product PanINSULA which can then be delivered to T1D patients as a naturally-acting alternative to existing solutions such as insulin therapy, CGMs and insulin pumps which requires careful and constant management. PanINSULA commercialisation will improve the quality of life of millions of patients suffering from diabetes.

PanCryos